-
Moderate to severe plaque psoriasis in adults who are candidates for systemic treatment or phototherapy
-
Active psoriatic arthritis in adults, either alone or in combination with other disease-modifying antirheumatic drugs (DMARDs)
Sale!
Tremfya 100mg
GUSELKUMAB
2-8* C
| MRP | : |
|
| Price | : | ₹108,000.00 |
| You Save | : | ₹10,126.00 (8.57%) |
1 Prefilled Syringe
Out of stock
Tremfya 100mg Injection contains Guselkumab, a human monoclonal antibody that is utilized for the treatment of chronic inflammatory conditions, such as moderate to severe plaque psoriasis and active psoriatic arthritis.
It is classified as an interleukin-23 (IL-23) inhibitor, which aids in alleviating inflammation resulting from an overactive immune response.
Tremfya 100mg Injection is recommended for adults who qualify for systemic therapy or phototherapy.
The medication functions by specifically targeting IL-23, a protein that plays a role in the abnormal immune responses associated with psoriasis and psoriatic arthritis.
This action contributes to the improvement of skin symptoms and the reduction of joint inflammation.
Common side effects may consist of upper respiratory tract infections, headaches, fatigue, joint pain, diarrhea, and reactions at the injection site.
If you notice any signs of a severe allergic reaction, infection, or difficulty in breathing, please reach out to your healthcare provider without delay.
